These medicines have low risk of hypoglycemia, provide beta cell protection, offer cardio-renal benefits and are safe for patients with kidney or liver conditions and senior citizens
Shanghai Public Health Clinical Center Completed the First Patient Dosing in Clinical Study of PD-L1 Antibody ASC22 in Combination with Chidamide for Functional Cure of HIV Infection
Companies finalize termination with an agreed-upon settlement fee of $55M to be paid to Akebia
First and only PARP inhibitor to improve invasive disease-free survival in patients
It´s the first trial to demonstrate the benefits of dual pathway inhibition
Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patients
COR803 is a novel small molecule 3CLpro inhibitor discovered and developed by Cortexyme based on its expertise in cysteine protease inhibition.
This new formulation represents a significant improvement over protease inhibitor-containing paediatric ARV formulations that have been used in South Africa for decades.
Alopecia areata usually presents as a few small bald patches in the head
Doubling of median overall survival seen in QuANTUM-First results presented at EHA Presidential Symposium
Subscribe To Our Newsletter & Stay Updated
